1 – 10 of 35
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease : a prospective cohort study
- Contribution to journal › Article
- 2025
-
Mark
Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice
- Contribution to journal › Article
-
Mark
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease
- Contribution to journal › Article
-
Mark
APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta
- Contribution to journal › Article
-
Mark
Validation status of cognitive digital assessments by the FDA BEST framework and context of use in preclinical AD studies : A systematic review
- Contribution to journal › Scientific review
-
Mark
Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease
- Contribution to journal › Article
-
Mark
Polygenic pathways shape white matter vulnerability to Alzheimer’s disease-related pathophysiological changes
- Contribution to journal › Article
-
Mark
Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease
- Contribution to journal › Article
-
Mark
Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum
- Contribution to journal › Article
-
Mark
The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease
- Contribution to journal › Article
